Castleview Partners’s Seagen Inc. Common Stock SGEN Stock Holding History

Castleview Partners’s Portfolio SGEN Stock Details SGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	-$257	–	725
2022 Q4	$257	Buy	+2	New	+$258	﹤0.01%	607

Other funds holding SGEN

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Castleview Partners's SGEN Position: Q1 2023 in Review

Castleview Partners sold out of Seagen Inc. Common Stock (SGEN) in Q1 2023, closing a stake of 2 shares — an estimated $257 sold.

Castleview Partners first reported a position in SGEN in Q4 2022 and held it in 1 quarter. The position peaked at $257 in Q4 2022. 575 funds tracked by Wall St. Rank hold SGEN as of Q1 2023.

Castleview Partners reported no remaining Seagen Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Castleview Partners sold 2 Seagen Inc. Common Stock shares in Q1 2023, an estimated $257.
Castleview Partners first reported a position in Seagen Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Castleview Partners's Seagen Inc. Common Stock position peaked at $257 in Q4 2022.
575 funds tracked by Wall St. Rank held Seagen Inc. Common Stock as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.